Study participants and raw data
malaria, stunting
OTHER MALARIA, MALARIA
Among the 579 children included in the analysis, 186 (32.1%) were HIV‐exposed. HIV‐exposed children were older when they began study drugs compared with HIV‐unexposed children (median age: 10 months vs. 6 months) and had lower median Z‐scores (Table Characteristics of study participants at the start of chemopreventionAbbreviations: DP, dihydroartemisinin‐piperaquine; SP, sulfadoxine‐pyrimethamine; TS, trimethoprim‐sulfamethoxazole.Continuous variables shown as median, (2.5th and 97.5th percentile).HIV‐exposed indicates children who are HIV‐uninfected but were born to HIV‐infected mothers.Underweight: weight‐for‐age z‐score < −2; Stunted: height‐for‐age z‐score < −2; Wasted: weight‐for‐height z‐score < −2; Other malaria prevention measures include keeping doors and windows closed in the evening, emptying/cover water sources.Kaplan‐Meier curves stratified by chemoprevention and nutritional status (stunted: height‐for‐age z‐score < −2 [orange line]; non‐stunted: height‐for‐age Z‐score ≥ −2 [blue line]). Time indicates time from beginning of chemoprevention to the subsequent malaria episode. DP, dihydroartemisinin‐piperaquine; SP, sulfadoxine‐pyrimethamine; TS, trimethoprim‐sulfamethoxazole.There were 500 PQ concentrations measured at the time of malaria (Kaplan‐Meier curves for HIV‐unexposed participants who received dihydroartemisinin‐piperaquine and had piperaquine concentrations measured (Height, weight, and age measurements were available from 27,890 (94.8%) of monthly study visits. Over 88% of measurements were below the WHO defined mean ZHA and 50% met the criteria for stunting (ZHA < ‐2) at least once. Children who never developed malaria between 6 months and 3 years of age trended towards being taller than those who had malaria greater than or equal to one time (92.7 cm vs. 91.6 cm, 